- Home
- VSTM vs INBX Comparison
VSTM vs INBX Comparison
Compare VSTM & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- INBX
- Stock Information
- Founded
- VSTM 2010
- INBX 2010
- Country
- VSTM United States
- INBX United States
- Employees
- VSTM N/A
- INBX N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- INBX Health Care
- Exchange
- VSTM Nasdaq
- INBX Nasdaq
- Market Cap
- VSTM 493.6M
- INBX 430.2M
- IPO Year
- VSTM 2012
- INBX 2020
- Fundamental
- Price
- VSTM $8.85
- INBX $68.65
- Analyst Decision
- VSTM Strong Buy
- INBX Hold
- Analyst Count
- VSTM 9
- INBX 2
- Target Price
- VSTM $13.38
- INBX N/A
- AVG Volume (30 Days)
- VSTM 2.2M
- INBX 609.5K
- Earning Date
- VSTM 11-04-2025
- INBX 11-13-2025
- Dividend Yield
- VSTM N/A
- INBX N/A
- EPS Growth
- VSTM N/A
- INBX N/A
- EPS
- VSTM N/A
- INBX N/A
- Revenue
- VSTM $2,137,000.00
- INBX $1,400,000.00
- Revenue This Year
- VSTM $79.32
- INBX $563.00
- Revenue Next Year
- VSTM $413.52
- INBX $230.77
- P/E Ratio
- VSTM N/A
- INBX N/A
- Revenue Growth
- VSTM N/A
- INBX N/A
- 52 Week Low
- VSTM $3.19
- INBX $10.81
- 52 Week High
- VSTM $11.25
- INBX $68.53
- Technical
- Relative Strength Index (RSI)
- VSTM 51.64
- INBX 81.38
- Support Level
- VSTM $7.60
- INBX $28.16
- Resistance Level
- VSTM $9.16
- INBX $39.27
- Average True Range (ATR)
- VSTM 0.66
- INBX 4.71
- MACD
- VSTM -0.02
- INBX 3.43
- Stochastic Oscillator
- VSTM 61.99
- INBX 97.37
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.